Background: Although the polycystic ovary syndrome (PCOS) is the most frequent endocrine disorder in women of reproductive age, its diagnosis remains one of the most challenging issues in endocrinology, gynecology, and reproductive medicine. The elevated levels of Anti-mullcrian hormone (AMH) in the women of PCOS strongly suggested that serum AMH levels may be used in the diagnosis of this condition. Laparoscopic ovarian diathermy (LOD) frequently induces ovulalion in patients with polycystic ovary syndrome (PCOS). The mechanism by which this effect occurs remains largely unexplained.
INTRODUCTION
induces the regression of the Mullerian ducts, the anlagcn of the female reproductive tract (8) . However. To establish the exact role of AMH in the pathophysiology of PCOS, we measured the plasma concentrations of AMH in a scries of PCOS women before and after LOD. the aim of the present study was to assess: 1) whether AMH could play a role in the diagnosis of PCOS, and 2) to assess any change of Anti-Mullerian Hormone after LOD and if this hormone has any role to play in the mechanism of action of LOD. To the best of our knowledge, no studies have been published about the possible AMH changes after ovarian surgery in PCOS patients " '.
MATERIALS & METHODS

Subjects:
Thirty women with anovulatory infertility associated with PCOS who were scheduled for LOD were prospectively included in this study between
and 2006. All women had polycystic ovaries
According to The Rotterdam criteria, 2003 (15) . The diagnosis of PCOS was based on the association of at least two of the three following criteria: 1) ovulatory disturbance, mainly oligomenorrhea or amenorrhea,
2) hyperandrogenism (HA) as defined either clinically by hirsutism or severe acne/seborrhea, and/or biologically by a testosterone serum level greater than 0.7 ng/ml, and 3) more than 12 follicles in the 2-to 9-mm range in each ovary at U/S and/or an ovarian volume higher than 10 ml. All women had previously failed to respond to incremental doses of clomifene citrate. All women gave informed consent for laparoscopic ovarian drilling using diathermy. U/S measurements were taken in real time, according to a standardized protocol, as previously described "*\
Controls:
The control population consisted of 10 women who were infertile due to tubal and/or male infertility.
No clinical biochemical or US evidences of PCOS.
Collection of blood samples:
Blood samples were taken from PCOS patients shortly before LOD at a random time in amenorrhoec women and early in the follicular phase (menstrual cycle day 2-4) in menstruating women. Further blood samples were obtained 1 week after surgery.
Hormonal assays:
The hormone assays for FSH, LH, testosterone and progesterone were performed using the electrochemiluminescence immunoassay " ECLTA" There was a trend toward lower FSH values in PCOS patients than in controls. The mean scrum AMH level was about 3-fold higher in PCOS patients than in controls (P _ 0.001). Likewise, the 2-to 9-mm FNPO at U/S were about 3-fold higher in PCOS patients than in controls (P < 0.001). It was significantly related to the serum AMH levels, both in controls (table IV) . As expected, the 2-to 9mm FNPO followed the same in these three subgroups (ANOVA, P<0.05), whereas age did not exert a statistically significant effect (table IV) .
When the PCOS patients with abnormal cycles were gathered together (n=20), we observed that the AMH levels varied significantly (p=0,03) according Lo the absence (n=IO) cr the presence (n=20) of HA, as Values are expressed as the mean with the (SD). NS, Non significant. The data showed that most PCOS women in this study as expected, had higher body mass index values and higher serum levels of LH, testosterone, than controls. There was a trend toward lower FSH values in PCOS patients than in controls.
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The mean serum AMH level was about 3-fold higher in PCOS patients than controls and than the reported level in normal women "**, Also, the mean 2-to 9-mm FNPO at U/S was 3-fold higher in PCOS patients than in control women. It was also significantly related to the serum AMH levels, both in controls and in patients. Thus, all these data led to the conclusion that AMH could be the best available biological marker of the ovarian early antral FN, both in fertile and infertile normoovulatory women and in PCOS patients.
In this study AMH was also positively related to the serum testosterone level in both groups (r=0.225 women with PCOS had a higher mean serum AMH levels than their oligomenorrheic patients.
In conclusion, it can be proposed from the present study that single measurement of AMH in the early follicular phase in women with HA and/or oligo-anovulation could indicate to the clinicians the presence of PCO when reliable U/S is not available.
However, it must be kept in mind that neither a high value of AMH nor a high FNPO is per se is sufficient to ascertain PCOS. Both criteria need to be incorporated into the PCO diagnosis.
In the present study, no significant correlation was observed between FSH, E2, BMI and AMH levels in PCOS patients and controls.
AMH and BMI:
In this study, no significant correlation was AMH and FSH and E2.
In this study, no significant correlation was observed between AMH and FSH mid E2 . Knowledge of the scrum AMH levels in such conditions might provide more insight into the possible cause or effect of altered AMH levels after LOD.
